The Science Behind ALS Treatments: Riluzole, Radicava, and Relyvrio Description

Moderated by Dr. Senda Ajroud-Driss, this webinar for both clinicians and people living with ALS will review the 3 drugs that are currently FDA-approved in the United States for the general ALS population. Panelists, Dr. Lauren Elman, Dr. John Novak, and Dr. Xiaowei (Bill) Su will present information on Riluzole, Radicava, and Relyvrio, including drug mechanism, findings from clinical trials, and potential benefits, risks, and costs.

Neals logo